Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/19/2025

Dapagliflozin Management Guidelines

Introduction to Dapagliflozin

  • The American College of Cardiology recommends monitoring patients taking dapagliflozin annually for kidney function through eGFR and urinary albumin:creatinine ratio assessment, and educating them about potential side effects including genital mycotic infections, urinary tract infections, and diabetic ketoacidosis 1

Dosing and Administration

  • Initial dosing of dapagliflozin is 5 mg orally once daily for glycemic control, which can be increased to 10 mg once daily for additional glycemic control and for cardiovascular and kidney protection 1
  • The American Journal of Kidney Diseases recommends not using dapagliflozin for glycemic control in patients with eGFR <45 mL/min/1.73m², but it can be used for cardiovascular and kidney protection with eGFR as low as 20-30 mL/min/1.73m² 1, 2, 3

Contraindications and Precautions

  • Dapagliflozin is not recommended for patients with severe kidney impairment (eGFR <45 mL/min/1.73m²) for glycemic control, but can be used with caution for cardiovascular and kidney protection 1, 2, 3
  • Discontinue dapagliflozin when dialysis is initiated, although limited evidence suggests it may be safe in dialysis patients 3

Benefits and Efficacy

  • Dapagliflozin reduces the risk of cardiovascular death and hospitalization for heart failure, sustained eGFR decline and kidney failure, particularly in patients with eGFR ≥20 mL/min/1.73m² and urinary albumin:creatinine ratio ≥200 mg/g 1, 2, 3

Monitoring and Management

  • Annual screening for kidney disease (eGFR and urinary albumin:creatinine ratio) is recommended for patients taking dapagliflozin 2
  • Monitor patients for signs of volume depletion, urinary tract infections, genital mycotic infections, and diabetic ketoacidosis, particularly during acute illness or fasting 3, 4
  • Educate patients on genital hygiene, sick day management protocol, recognition of DKA symptoms, importance of adequate hydration, and self-monitoring for signs of urinary tract infections 3, 4, 5

Adverse Effects

  • Genital mycotic infections are the most common adverse effect of dapagliflozin, particularly in women, and can be mitigated with education on genital hygiene 3
  • Urinary tract infections and diabetic ketoacidosis are rare but serious adverse effects that require prompt medical attention 4

Special Considerations

  • Dapagliflozin may facilitate the use of other guideline-directed therapies (RAS inhibitors, mineralocorticoid receptor antagonists) by reducing hyperkalemia risk 3
  • Consider reducing doses of insulin or insulin secretagogues when used with dapagliflozin to reduce hypoglycemia risk 3

Tables